

ASIAN JOURNAL OF SCIENCE AND TECHNOLOGY

Asian Journal of Science and Technology Vol. 09, Issue, 02, pp.7519-7521, February, 2018

RESEARCH ARTICLE

TRILATERAL RETINOBLASTOMA: A CASE REPORT

*1MAKITA, Chantal, 1NGANGA NGABOU Géraud Charles Freddy, 2NSONDE MALANDA Judith, 3MASSAMBA Alphonse

¹Ophtalmology Department, Teaching University Hospital of Brazzaville, Congo
²Cancer and Radiotherapy Department, Teaching University Hospital of Brazzaville, Congo
³Biostatistics and Biosciences Department, Brazzaville Institute of Health and Sports, Marien NGOUABI University, Brazzaville-Congo

ARTICLE INFO

ABSTRACT

Article History:

Received 13th November, 2017 Received in revised form 26th December, 2017 Accepted 06th January, 2018 Published online 28th February, 2018

Key words:

Trilateral retinoblastoma, Scanner, Chemotherapy. We report the case of a 2-year-old child with no history especially access the service at the age of one month for intraocular retinoblastoma unilat right. Then eighten months later there was a location in the left eye. The patient is seen 20 months later with large bilateral tumors of both orbits extending towards the zeugmatic area on right and the front left area. Oculars structures are covered with two larges chemosis. The objective brain scan large tumor in the brain. The treatment consisted of chemotherapy with Vincristine-Adriblastine-Cyclophosphamide-Etoposide protocol. After sixth treatment we found a significant decrease in tumor volume. Then child is lost.

Copyright © 2018, MAKITA, Chantal at al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Presentation

Retinoblastoma is a highly malignant tumor and the most common intraocular tumor in children (El Kettani, 2014). The diagnosis is essentially clinical, the prognosis is excellent in developed countries where the survival is of the order of 95% (Lumbroso-Le Rouic, 2008 and Balmer, 2008). In the Congo and in the developing countries it is diagnosed very late, in a highly evolved form with high mortality (NsondéMalanda, 2011 and Sow, 2014). Trilateral retinoblastoma is rare, in Burkina three cases had been reported. It is defined as an association of an intraocular neuroblastic tumor and an inherited or bilateral hereditary retinoblastoma most often, sometimes sporadic (Blach, 1999). The tumor of the brain is considered a primary tumor and not a metastasis (Zografos, 2002). We report a case.

Medical History

2-year-old male infant, with no specific history according to parents, is seen at 1 month of age in the leukocoria department, ophthalmic examination with fundus revealed unilateral retinoblastoma right intraocular stage.

*Corresponding author: MAKITA, Chantal,

Ophtalmology Department, Teaching University Hospital of Brazzaville, Congo

The pediatric examination was normal. A B-mode echocardiography and an orbito-cerebral tomodensitometry had been proposed to supplement the clinical examination not performed by the parents for lack of financial means and even asked for the child's foolishness. Then 6 months later, according to the parents they found another location of the intraocular tumor in the left eye. The patient returned 20 months later with a voluminous bilateral tumor of both orbits, extending to the zygomatic region on the right and the frontal region on the left, thus exceeding the Reese-Elsworth stage V. The ocular structures are inaccessible and covered by two large chemosis (Figure 1). The cerebral CT scan described a large tumor of 40 X 30 mm in the brain (Figure 2).

Workup and Treatment

The therapeutic management carried out in the carcinology department consisted of chemotherapy with the Vincristine-Adriblastine-Cyclophosphamide-Etoposide protocol in 6 courses for 3 months. In the first month, the patient received three courses of treatment two weeks apart under the control of a blood count, the second month two courses spaced 3 weeks apart and the last month a single course. We have seen a clear regression of the tumor from the first treatment (Figure 3) and this gradually until the 5th cure (Figure 4). Then the child is lost sight of.



Figure 1. Bilateral retinoblastoma



Figure 3. After the 1st chemotherapy treatment

The present clinical case shows the existence of this

DISCUSSION

retinoblastoma entity in our country made of the association of the tumor of the brain that appeared 20 months after the discovery of bilateral retinoblastoma. This corroborates with data from the literature on the average time to onset of brain injury that is at least 21 months for KIVELA (Kivëla, 1999). The pathophysiology of this syndrome is not well known. It has been suggested that the intracranial tumor derives from pinealoblasts. Marcus et al. (Marcus, 1998) notes another origin that of the germinal strain of primitive neuroblasts under ependymaires not intended for a pineal differentiation. It could therefore be considered as a primary neuroectodermal tumor. CT and MRI are the only preferred complementary examinations of retinoblastoma. They have the advantage of locating the intraocular tumoral lesions to analyze the locoregional extension and to evaluate a possible intracranial localization of the tumor. They also allow evolutionary followup (Nikièma, 2009). But these exams are not easy to access because of the very high cost in our countries. Therapeutic management required the intervention of oncologists where a chemotherapy treatment was instituted and very beneficial for our case. Namely that high cost of drugs and side effects are constraints to further treatment. Some authors believe that chemotherapy associated with local treatments gives good results on tumor control and ocular conservation given the sensitivity of this tumor (El Kettani, 2014; Balmer, 2008; NsondéMalanda, 2011; Sow, 2014; Blach, 1999 and Zografos,




Figure 2. Cerebral computed tomography with brain tumor



Figure 4. After the 5th chemotherapy treatment

2002). But the question remains to ask what about the cerebral involvement? We could not perform a second scan to evaluate the tumor regression at the cerebral level. According to the literature, involvement of the central nervous system suggests a fatal event (Gündüz, 2006).

Conclusion

Trilateral retinoblastoma is rare but present in our country. It is an expensive tumor of diagnosis and dark prognosis which poses a therapeutic challenge.

REFERENCES

Balmer, A., Munier, F., Zografos, L. 2008. Nouvelles stratégies thérapeutiques en Oncologie Ophtalmomo-Pédiatrique. *Rev Med Suisse*, 16:139-43.

Blach, L.E., Laroche, G.R. 1999. Successful treatment of neonatal trilatéralrétinoblastoma. *J Aopos.*, 3 : 376-8.

El Kettani, A., Aderdour, S., Daghoug, G., Kinari, S., Zaghloul, K., Zafad, S., Harif, M., Benchekroun, S. 2014. Rétinoblastome: résultats préliminaires du protocole national de prise charge au CHU de Casablanca. *J Fr Ophtalmol.*, 37 (2): 115-124.

Gündüz, K., Muftüoglu, O., Unal, E., Tacyildiz, N. 2006. Metastasic retinoblastoma clinical features, treatment, and prognosis. *Ophtalmology*, 113 (9): 1558-66.

- Kivëla, T. 1999. Trilatéralretinoblastoma: a meta analysis of hereditary retinoblastoma associeted with primary ectopic intracranial retinoblastoma. *J Clin Oncol.*, 17: 1829-37.
- Lumbroso-Le Rouic, L., Aerts, I., Lévy-Gabriel, C., Dendale, R., Sastre, X., Esteve, M., et al. 2008. Conservative treatment of intraocular retinobastoma. *Ophtalmology*, 115: 1405-10.
- Marcus, D.M., Brooks, S.E., Leef, G., et al. 1998. Trilateral retinoblastoma: Insight intohistogenesis and management. *Surv Ophtalmol.*, 43:59-70.
- Nikièma, Z., Diallo, J.W., Daboué, A., Traoré, S.S., Traoré zorom, B., Bamouni, A., Lougoué Sorgho, C., Cissé, R. 2009. Rétinoblastome trilatéral en milieu Burkinabé: à propos de trois cas. Cahiers Santé, vol 19, n°4 oct-nov-dec 184-8.
- NsondéMalanda, J., Makita Bagamboula, C., Bambara, T.A., Makosso, E., GombéMbalawa, C. 2011. Le traitement du rétinoblastome au CHU de Brazzaville. *Carcinol Clin Afrique*, 10(2): 34-39.
- Sow, A.S., Ndoye Roth, P.A., Moreira, C., DiagneAkondé, F.B., Ka, A.M., Ndiaye Sow, M.N., Ba, E.A., Wane Khouma, A.M., Ndiaye, M.R. 2014. Thérapeutique du Rétinoblastome: expérience sénégalaise. *J Fr Ophtalmol* 37 (5): 381-7.
- Zografos, L. 2002. Tumeurs intraoculaires, Paris Société Française d'Ophtalmologie et Masson.
